The MeCo Score™ is the first and only clinically validated biomarker test to help with therapy selection for patients with early-stage breast cancer who have a higher risk of progression (1,2) and may benefit from FDA-approved antifibrotic therapy (3)*.
Partnerships & Collaborations
Funding
Awards & Affiliations
References
[1] Watson, A.W. et al. (2021). Cell Reports. 29;35(13):109293. doi: 10.1016/j.celrep.2021.109293
[2] Data on file with Cleveland Clinic and MeCo Diagnostics Holdings, Inc.
[3] Data on file with the Spanish National Cancer Research Center (CNIO) and MeCo Diagnostics Holdings, Inc. The prescribing information for the FDA-approved therapy may not include a an associated biomarker, and the indication of use for the MeCo Score may be more specific with regard to TNM cancer staging than currently proposed.
*The MeCo Score (TM) assay is for Investigational Use Only
and is not cleared or approved by the Food and Drug Administration.
Copyright © 2024 MeCo Diagnostics Holdings, Inc. - All Rights Reserved.